Last reviewed · How we verify
Delysid (LYSERGIDE)
Delysid works by binding to the 5-hydroxytryptamine receptor 2A, a subtype of serotonin receptor.
Delysid (LYSERGIDE) is a small molecule lysergide that targets the 5-hydroxytryptamine receptor 2A. Its mechanism of action is not FDA-approved, and it is not commercially available. As a result, there is limited information available on its approved indications, half-life, bioavailability, generic manufacturers, and commercial status. Delysid is not a widely recognized or approved medication, and its development and commercialization status are unclear. Further research is needed to understand its potential therapeutic applications and safety considerations.
At a glance
| Generic name | LYSERGIDE |
|---|---|
| Drug class | lysergide |
| Target | 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A, 5-hydroxytryptamine receptor 6 |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Mechanism of action
Imagine your brain cells are like locks, and serotonin is the key that unlocks them. Delysid is a special key that fits into a specific lock, called the 5-hydroxytryptamine receptor 2A, which helps regulate mood and other functions. By binding to this lock, Delysid can influence how serotonin works in the brain.
Approved indications
Common side effects
- Drug abuse
- Drug dependence
- Intentional product misuse
- Alcohol abuse
- Substance abuse
Key clinical trials
- Long-term Efficacy and Safety of LSD Versus TIPS for Cirrhotic Portal Hypertension Bleeding and Hypersplenism (NA)
- Pharmacokinetics of Didehydro-LSD (DDH-LSD) Compared With LSD (NA)
- A Dose-Finding Study of MM120 (LSD D-Tartrate) for the Treatment of Anxiety Symptoms (PHASE2)
- Safety and Efficacy of Low Dose MM120 for ADHD Proof of Concept Trial (PHASE2)
- Effect of Ketanserin, Olanzapine, and Lorazepam After LSD Administration on the Acute Response to LSD in Healthy Subjects (PHASE1)
- Retrospective Observational Study of Intensity Effects in Psychedelic-assisted Treatment
- Microdosing LSD in Women With Premenstrual Disorders (NA)
- Lysergic Acid Diethylamide (LSD) in Palliative Care (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Delysid CI brief — competitive landscape report
- Delysid updates RSS · CI watch RSS